What Is MRSP Infection in Dogs and How Is It Treated?

Methicillin-resistant Staphylococcus pseudintermedius, or MRSP, is a drug-resistant bacterium that primarily infects dogs and has become one of the most challenging infectious disease problems in veterinary medicine over the past two decades. The bacterium shrugs off the entire class of beta-lactam antibiotics, which includes many of the drugs veterinarians reach for first, and most MRSP strains resist several additional drug families on top of that. For a pet owner hearing the acronym for the first time after a vet visit, the practical reality is a skin or ear infection that will not respond to standard antibiotics and may require a carefully tailored treatment plan.

What Staphylococcus pseudintermedius Actually Is

Staphylococcus pseudintermedius was formally described as a distinct species in 2005, after researchers showed it was genetically separate from the closely related S. intermedius and S. delphini.

¹ Before that reclassification, many veterinary labs were calling it S. intermedius, which means older research on staph infections in dogs likely included S. pseudintermedius without realizing it. The bacterium is coagulase-positive, meaning it can trigger blood clotting in lab tests, a trait it shares with S. aureus in humans. For dogs, it is a normal resident of the skin and mucous membranes. A systematic review of nasal carriage found that roughly one in five healthy dogs carries S. pseudintermedius in the nose, while the rate in cats is much lower, around one in a hundred.² Nasal sampling actually underestimates how many dogs carry the organism. A cross-sectional study that swabbed multiple body sites found S. pseudintermedius on about seven in ten dogs, with the perineum and mouth being the most common colonization sites.³

The key point is that most dogs harbor this bacterium as a harmless commensal. Problems start only when the skin barrier is disrupted by allergies, wounds, surgery, or immune suppression, giving the bacterium an opportunity to invade and multiply. When the strain that takes hold happens to be methicillin-resistant, that opportunistic infection becomes dramatically harder to treat.

Infections MRSP Causes in Dogs

The most common MRSP infection by far is pyoderma, the medical term for a bacterial skin infection. In dogs, pyoderma usually appears as red bumps, pustules, crusting, hair loss, and itchy or inflamed patches. MRSP is also a frequent cause of otitis externa (outer ear infections), surgical-site infections, and urinary tract infections. Less commonly it can involve the respiratory tract or reproductive organs.⁴ Pyoderma in particular tends to recur when the underlying cause, often allergic skin disease, is not managed alongside the infection itself.

Why MRSP Is So Hard to Treat

MRSP carries the mecA gene, which encodes an altered protein that beta-lactam antibiotics cannot bind to. Because beta-lactams are a huge class of drugs, including penicillins, cephalosporins, and carbapenems, the mecA gene alone wipes out a large portion of the antibiotic toolbox in one stroke. But most MRSP strains don’t stop there. A study of dogs with pyoderma in Peru found that about a quarter of S. pseudintermedius isolates carried mecA, and among those, roughly three-quarters were multidrug-resistant, meaning they resisted at least three different antibiotic families.⁵ In that study, resistance was highest against lincosamides, cephalosporins, and sulfonamides, while amoxicillin-clavulanate still worked against most strains. Two isolates resisted every antibiotic family tested.

This kind of multidrug resistance is not unusual for MRSP globally. The resistance genes tend to cluster together on mobile genetic elements, so when a strain picks up mecA, it often acquires resistance to fluoroquinolones, aminoglycosides, and other classes at the same time. A genomic characterization of the first MRSP isolated from a human patient in Argentina found resistance to six antibiotic classes, consistent with the resistance genes in its genome.⁶

Biofilm and Why Infections Linger

Beyond antibiotic resistance genes, MRSP has another trick that makes infections stubborn: biofilm. Biofilm is a slimy, self-produced matrix that bacteria secrete around themselves, forming a protective shell on surfaces like skin, wound tissue, or implanted medical devices. Studies have found that the vast majority of S. pseudintermedius isolates are strong or moderate biofilm producers, with one study classifying 96% of isolates that way.⁷ This ability does not appear to differ between methicillin-resistant and methicillin-susceptible strains, meaning it is a feature of the species itself rather than something linked specifically to resistance.⁸ For the pet owner, biofilm explains why an MRSP skin infection can seem to improve and then flare up again. Bacteria protected inside a biofilm are shielded from both antibiotics and the immune system, and they can reseed the infection once conditions change.

Risk Factors for MRSP Infection

Not every dog that carries S. pseudintermedius will develop an MRSP infection. Certain circumstances push the odds higher. A German case-control study found that hospitalization was by far the strongest risk factor, with hospitalized animals having dramatically elevated odds of MRSP infection compared to non-hospitalized animals. Frequent veterinary clinic visits, use of glucocorticoid medications (steroids), and topical ear medications also increased the risk.⁹ Interestingly, that study found no clear link between prior antibiotic use and MRSP infection, which the authors speculated might mean MRSP is so well adapted to canine skin that it does not need antibiotic selective pressure to thrive.

Other research tells a somewhat different story on antibiotics. A study looking at superficial pyoderma and owners found that dogs that had received antimicrobial treatment within the previous month were at significantly higher risk of MRSP infections.¹⁰ The discrepancy likely reflects differences in study design and population, but the take-home message is that both healthcare exposure and prior antibiotics are plausible drivers, and the clearest risk factor is repeated contact with clinical veterinary settings.

Global Spread and Dominant Strains

MRSP is not confined to one region. A systematic review of global epidemiology identified several dominant genetic lineages spreading internationally. The strain cluster known as CC71, once called the “epidemic European clone,” has now been found on every continent where researchers have looked. North America has its own widespread lineage, CC68, though CC68 also appears in European surveys. Asia tends to see CC45 and CC112 more frequently, while in parts of Europe a lineage called CC258 has been rising in prevalence.¹¹ These lineages differ in which additional resistances they carry. CC258, for instance, tends to remain susceptible to certain fluoroquinolones and aminoglycosides while resisting sulfonamides more frequently than CC71. That matters to clinicians because knowing the local dominant strain can help predict which backup drugs might still work before lab results come back.

Diagnosis

Diagnosing MRSP starts with identifying the bacterium and then determining its resistance profile. Culture and sensitivity testing from a properly collected skin, ear, or wound sample is the standard approach. Labs grow the organism, confirm it is S. pseudintermedius, and then test it against a panel of antibiotics. Detecting methicillin resistance specifically can be done using an oxacillin disc diffusion test, which outperforms the cefoxitin disc test commonly used for detecting methicillin resistance in human S. aureus infections.¹² Labs can also test directly for the mecA gene by PCR for a definitive answer. The practical takeaway for pet owners is that if your dog has a skin infection that is not responding to a standard antibiotic, your vet should culture the infection rather than simply switching to another drug blind.

Treatment Options

The good news about MRSP pyoderma, which is the most common presentation, is that superficial skin infections can often be managed with topical therapy alone. A randomized trial compared a chlorhexidine shampoo-and-solution protocol against systemic amoxicillin-clavulanate for superficial pyoderma and found that the topical chlorhexidine protocol resolved clinical signs in all treated dogs, including those infected with MRSP.¹³ This supports current guidelines that recommend topical antiseptic therapy as the first-line approach for superficial pyoderma, which sidesteps the resistance problem entirely. Chlorhexidine works through direct contact killing, which bacteria do not develop resistance to as readily as they do to antibiotics.

For deeper or systemic infections where topical therapy alone is insufficient, the choice of antibiotic must be guided by culture and sensitivity results. International guidelines from the companion animal infectious diseases community use a tiered approach, with certain drugs reserved strictly for highly resistant infections and recommended only in consultation with a veterinary specialist.¹⁴ These last-resort drugs may include agents like chloramphenicol, rifampin, or aminoglycosides depending on what the sensitivity panel shows. The reluctance to use them casually is deliberate: if MRSP develops resistance to these too, treatment options would become extremely limited.

What Happens After Treatment

Even after an MRSP infection clears clinically, the bacterium does not always leave. A follow-up study found that among dogs whose MRSP pyoderma was cured, about 45% still had MRSP on their skin and nearly half still carried it at other body sites.¹⁵ This persistent colonization is why recurrent MRSP infections are a genuine concern. A dog can look and feel fine for weeks or months, then have a flare when its skin barrier is compromised again by allergies, a hot spot, or another trigger.

Longitudinal household studies confirm that once MRSP enters a home, dogs can remain carriers for prolonged periods and can test positive again after repeated negative samplings. The environment, including bedding, floors, and shared surfaces, can also harbor the organism and serve as a reservoir for reinfection.¹⁶ Managing the underlying condition that predisposes the dog to infection, most commonly allergic skin disease, is just as important as treating the MRSP itself.

Can MRSP Spread to People?

This is one of the first questions owners ask, and the honest answer is: it can, but it rarely does and almost never causes lasting colonization. A household transmission study found MRSP on about 4% of human contacts in homes and 3% of veterinary clinic personnel, but these appeared to be transient contamination events rather than true colonization.¹⁷ Another study tracking households with infected dogs found that owners occasionally tested positive for methicillin-susceptible S. pseudintermedius but remained negative for the resistant form even when MRSP was consistently present in the environment.¹⁸ The longitudinal household data reinforce this: humans were never found MRSP-positive more than once, suggesting contamination rather than true colonization.¹⁹

That said, S. pseudintermedius can occasionally cause infections in immunocompromised people or those with open wounds. The case from Argentina describing a multidrug-resistant MRSP in a human patient demonstrates that zoonotic infections do happen, even if they are rare.²⁰ Transmission to other pets in the household is a more significant concern. Contact animals become colonized much more frequently than humans, especially when the infected dog still has active clinical signs.²¹

Hygiene in the Home and at the Clinic

Infection control matters both at home and in veterinary facilities. A large outbreak at a Finnish veterinary teaching hospital illustrates what it takes to contain MRSP in a clinical setting. Control measures included alcohol-based hand rubs before and after every patient contact, protective gowns and gloves for procedures involving wounds or bodily fluids, a strict clean-before-dirty workflow (healthy patients seen before sick ones), and surface disinfection with a virucidal agent after contact with known carriers.²² For owners at home, the principles are simpler but follow the same logic: wash hands after handling infected areas or applying topical treatments, launder bedding frequently in hot water, and keep the infected dog separated from other pets in the household as much as practical while the infection is active.

The Financial and Emotional Weight

An MRSP diagnosis can strain an owner’s budget and patience. The infection often requires repeated veterinary visits, culture-and-sensitivity testing that is more expensive than a simple prescription, specialty topical products, and sometimes consultation with a veterinary dermatologist. Treatment timelines stretch longer than they would for a susceptible infection, and recurrence rates are high enough that some owners go through the cycle multiple times. Antibiotic resistance in companion animals can carry real social and economic consequences for owners, and hospital-acquired outbreaks can impose costs on the clinics themselves.²³ None of this is trivial for people who consider their pets family members and want the best care without an endless bill.

Phage Therapy and What May Come Next

Because antibiotic options are shrinking, researchers are investigating alternatives. One of the most promising is phage therapy, which uses viruses that specifically infect and kill bacteria. A recent study tested bacteriophages against MRSP in a canine pyoderma model and found that the combination of phages with antibiotics produced the most significant therapeutic effect, outperforming phages alone and far outperforming antibiotics alone. In fact, the antibiotic-only group showed no significant improvement over the untreated controls.²⁴ Beyond killing the bacteria directly, the phages appeared to restore the bacteria’s sensitivity to antibiotics, a phenomenon called phage-antibiotic synergy that has been observed in other resistant organisms as well. Phage therapy is not yet widely available in clinical veterinary practice, but these results suggest it could eventually become a real option for infections that resist everything else in the medicine cabinet.

Other avenues being explored include antimicrobial peptides, photodynamic therapy (using light-activated compounds to kill bacteria on the skin surface), and novel anti-biofilm agents. The biofilm problem is a particular focus, because an anti-biofilm treatment that strips the protective matrix could, in theory, make existing antibiotics effective again even against otherwise resistant strains. None of these approaches are ready for routine clinical use, but the research pipeline reflects how seriously the veterinary community takes the MRSP problem.